APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Insulin Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Long-acting Insulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025192 pages

Choose your research edition.

Industry ResearchLong-acting Insulin Injection Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Insulin Injection Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Long-acting Insulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Insulin Injection Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Insulin Injection Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Long-acting Insulin Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Long-acting Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Long-acting Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting Insulin Injection include United Laboratories, Tonghua Dongbao, Sanofi, Novo Nordisk, Eli Lilly & Co, Gan & Lee, Wockhardt, Viatris and Swixx Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Insulin Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Insulin Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Insulin Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Insulin Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Insulin Injection Segment by Company

United Laboratories

Tonghua Dongbao

Sanofi

Novo Nordisk

Eli Lilly & Co

Gan & Lee

Wockhardt

Viatris

Swixx Biopharma

Lupin Laboratories

KALBE PHARMA

INFION PHARMA

Cipla

Biocon Biologics

Biocare

Abbott Laboratories

Long-acting Insulin Injection Segment by Type

Insulin Glargine

Insulin Detemir

Insulin Degludec

Long-acting Insulin Injection Segment by Application

Type 1 Diabetes

Type 2 Diabetes

Long-acting Insulin Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Insulin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Insulin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Insulin Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Insulin Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting Insulin Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Long-acting Insulin Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Long-acting Insulin Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Long-acting Insulin Injection Industry Trends Table 2. Long-acting Insulin Injection Industry Drivers Table 3. Long-acting Insulin Injection Industry Opportunities and Challenges Table 4. Long-acting Insulin Injection Industry Restraints Table 5. Global Long-acting Insulin Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Long-acting Insulin Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Long-acting Insulin Injection Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Long-acting Insulin Injection Sales Market Share by Manufacturers Table 9. Global Long-acting Insulin Injection Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Long-acting Insulin Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Long-acting Insulin Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Long-acting Insulin Injection Manufacturers, Product Type & Application Table 13. Global Long-acting Insulin Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Insulin Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Insulin Glargine Table 17. Major Manufacturers of Insulin Detemir Table 18. Major Manufacturers of Insulin Degludec Table 19. Global Long-acting Insulin Injection Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Long-acting Insulin Injection Sales by Type (2021-2026) & (k units) Table 21. Global Long-acting Insulin Injection Sales by Type (2027-2032) & (k units) Table 22. Global Long-acting Insulin Injection Sales Market Share by Type (2021-2026) Table 23. Global Long-acting Insulin Injection Sales Market Share by Type (2027-2032) Table 24. Global Long-acting Insulin Injection Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Long-acting Insulin Injection Revenue by Type (2021-2026) & (k units) Table 26. Global Long-acting Insulin Injection Revenue by Type (2027-2032) & (k units) Table 27. Global Long-acting Insulin Injection Revenue Market Share by Type (2021-2026) Table 28. Global Long-acting Insulin Injection Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Type 1 Diabetes Table 30. Major Manufacturers of Type 2 Diabetes Table 31. Global Long-acting Insulin Injection Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Long-acting Insulin Injection Sales by Application (2021-2026) & (k units) Table 33. Global Long-acting Insulin Injection Sales by Application (2027-2032) & (k units) Table 34. Global Long-acting Insulin Injection Sales Market Share by Application (2021-2026) Table 35. Global Long-acting Insulin Injection Sales Market Share by Application (2027-2032) Table 36. Global Long-acting Insulin Injection Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Long-acting Insulin Injection Revenue by Application (2021-2026) & (k units) Table 38. Global Long-acting Insulin Injection Revenue by Application (2027-2032) & (k units) Table 39. Global Long-acting Insulin Injection Revenue Market Share by Application (2021-2026) Table 40. Global Long-acting Insulin Injection Revenue Market Share by Application (2027-2032) Table 41. Global Long-acting Insulin Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Long-acting Insulin Injection Sales by Region (2021-2026) & (k units) Table 43. Global Long-acting Insulin Injection Sales Market Share by Region (2021-2026) Table 44. Global Long-acting Insulin Injection Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Long-acting Insulin Injection Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Long-acting Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 48. North America Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 49. Europe Long-acting Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 51. Europe Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Long-acting Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Long-acting Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 58. Global Long-acting Insulin Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Long-acting Insulin Injection Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Long-acting Insulin Injection Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Long-acting Insulin Injection Revenue Market Share by Region (2021-2026) Table 62. Global Long-acting Insulin Injection Revenue Market Share by Region (2027-2032) Table 63. United Laboratories Company Information Table 64. United Laboratories Business Overview Table 65. United Laboratories Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. United Laboratories Long-acting Insulin Injection Product Portfolio Table 67. United Laboratories Recent Development Table 68. Tonghua Dongbao Company Information Table 69. Tonghua Dongbao Business Overview Table 70. Tonghua Dongbao Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Tonghua Dongbao Long-acting Insulin Injection Product Portfolio Table 72. Tonghua Dongbao Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi Long-acting Insulin Injection Product Portfolio Table 77. Sanofi Recent Development Table 78. Novo Nordisk Company Information Table 79. Novo Nordisk Business Overview Table 80. Novo Nordisk Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novo Nordisk Long-acting Insulin Injection Product Portfolio Table 82. Novo Nordisk Recent Development Table 83. Eli Lilly & Co Company Information Table 84. Eli Lilly & Co Business Overview Table 85. Eli Lilly & Co Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Eli Lilly & Co Long-acting Insulin Injection Product Portfolio Table 87. Eli Lilly & Co Recent Development Table 88. Gan & Lee Company Information Table 89. Gan & Lee Business Overview Table 90. Gan & Lee Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Gan & Lee Long-acting Insulin Injection Product Portfolio Table 92. Gan & Lee Recent Development Table 93. Wockhardt Company Information Table 94. Wockhardt Business Overview Table 95. Wockhardt Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Wockhardt Long-acting Insulin Injection Product Portfolio Table 97. Wockhardt Recent Development Table 98. Viatris Company Information Table 99. Viatris Business Overview Table 100. Viatris Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Viatris Long-acting Insulin Injection Product Portfolio Table 102. Viatris Recent Development Table 103. Swixx Biopharma Company Information Table 104. Swixx Biopharma Business Overview Table 105. Swixx Biopharma Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Swixx Biopharma Long-acting Insulin Injection Product Portfolio Table 107. Swixx Biopharma Recent Development Table 108. Lupin Laboratories Company Information Table 109. Lupin Laboratories Business Overview Table 110. Lupin Laboratories Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Lupin Laboratories Long-acting Insulin Injection Product Portfolio Table 112. Lupin Laboratories Recent Development Table 113. KALBE PHARMA Company Information Table 114. KALBE PHARMA Business Overview Table 115. KALBE PHARMA Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. KALBE PHARMA Long-acting Insulin Injection Product Portfolio Table 117. KALBE PHARMA Recent Development Table 118. INFION PHARMA Company Information Table 119. INFION PHARMA Business Overview Table 120. INFION PHARMA Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. INFION PHARMA Long-acting Insulin Injection Product Portfolio Table 122. INFION PHARMA Recent Development Table 123. Cipla Company Information Table 124. Cipla Business Overview Table 125. Cipla Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Cipla Long-acting Insulin Injection Product Portfolio Table 127. Cipla Recent Development Table 128. Biocon Biologics Company Information Table 129. Biocon Biologics Business Overview Table 130. Biocon Biologics Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Biocon Biologics Long-acting Insulin Injection Product Portfolio Table 132. Biocon Biologics Recent Development Table 133. Biocare Company Information Table 134. Biocare Business Overview Table 135. Biocare Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Biocare Long-acting Insulin Injection Product Portfolio Table 137. Biocare Recent Development Table 138. Abbott Laboratories Company Information Table 139. Abbott Laboratories Business Overview Table 140. Abbott Laboratories Long-acting Insulin Injection Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Abbott Laboratories Long-acting Insulin Injection Product Portfolio Table 142. Abbott Laboratories Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Long-acting Insulin Injection Distributors List Table 146. Long-acting Insulin Injection Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Long-acting Insulin Injection Product Image Figure 2. Global Long-acting Insulin Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Insulin Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Insulin Injection Sales (2021-2032) & (k units) Figure 5. Global Long-acting Insulin Injection Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Long-acting Insulin Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Insulin Glargine Image Figure 9. Insulin Detemir Image Figure 10. Insulin Degludec Image Figure 11. Global Long-acting Insulin Injection Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Long-acting Insulin Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Long-acting Insulin Injection Sales Market Share by Type (2021-2032) Figure 14. Global Long-acting Insulin Injection Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Long-acting Insulin Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Long-acting Insulin Injection Revenue Market Share by Type (2021-2032) Figure 17. Type 1 Diabetes Image Figure 18. Type 2 Diabetes Image Figure 19. Global Long-acting Insulin Injection Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Long-acting Insulin Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Long-acting Insulin Injection Sales Market Share by Application (2021-2032) Figure 22. Global Long-acting Insulin Injection Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Long-acting Insulin Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Long-acting Insulin Injection Revenue Market Share by Application (2021-2032) Figure 25. North America Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 27. U.S. Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 32. Germany Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 39. China Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 47. Brazil Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Long-acting Insulin Injection Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Long-acting Insulin Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Long-acting Insulin Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Long-acting Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 58. North America Long-acting Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Long-acting Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 60. Europe Long-acting Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Long-acting Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Long-acting Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Long-acting Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Long-acting Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Long-acting Insulin Injection Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Long-acting Insulin Injection Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Glargine
  • Insulin Detemir
  • Insulin Degludec
Applications
  • Type 1 Diabetes
  • Type 2 Diabetes
Companies covered
  • United Laboratories
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Eli Lilly & Co
  • Gan & Lee
  • Wockhardt
  • Viatris
  • Swixx Biopharma
  • Lupin Laboratories
  • KALBE PHARMA
  • INFION PHARMA
  • Cipla
  • Biocon Biologics
  • Biocare
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting Insulin Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting Insulin Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Long-acting Insulin Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Long-acting Insulin Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Long-acting Insulin Injection Market Dynamics
  1. 2.1 Long-acting Insulin Injection Industry Trends
  2. 2.2 Long-acting Insulin Injection Industry Drivers
  3. 2.3 Long-acting Insulin Injection Industry Opportunities and Challenges
  4. 2.4 Long-acting Insulin Injection Industry Restraints
3 Long-acting Insulin Injection Market by Manufacturers
  1. 3.1 Global Long-acting Insulin Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Long-acting Insulin Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Long-acting Insulin Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Long-acting Insulin Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting Insulin Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Long-acting Insulin Injection Manufacturers, Product Type & Application
  7. 3.7 Global Long-acting Insulin Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting Insulin Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting Insulin Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting Insulin Injection Tier 1, Tier 2, and Tier 3
4 Long-acting Insulin Injection Market by Type
  1. 4.1 Long-acting Insulin Injection Type Introduction
  2. 4.1.1 Insulin Glargine
  3. 4.1.2 Insulin Detemir
  4. 4.1.3 Insulin Degludec
  5. 4.2 Global Long-acting Insulin Injection Sales by Type
  6. 4.2.1 Global Long-acting Insulin Injection Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long-acting Insulin Injection Sales by Type (2021-2032)
  8. 4.2.3 Global Long-acting Insulin Injection Sales Market Share by Type (2021-2032)
  9. 4.3 Global Long-acting Insulin Injection Revenue by Type
  10. 4.3.1 Global Long-acting Insulin Injection Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Long-acting Insulin Injection Revenue by Type (2021-2032)
  12. 4.3.3 Global Long-acting Insulin Injection Revenue Market Share by Type (2021-2032)
5 Long-acting Insulin Injection Market by Application
  1. 5.1 Long-acting Insulin Injection Application Introduction
  2. 5.1.1 Type 1 Diabetes
  3. 5.1.2 Type 2 Diabetes
  4. 5.2 Global Long-acting Insulin Injection Sales by Application
  5. 5.2.1 Global Long-acting Insulin Injection Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Long-acting Insulin Injection Sales by Application (2021-2032)
  7. 5.2.3 Global Long-acting Insulin Injection Sales Market Share by Application (2021-2032)
  8. 5.3 Global Long-acting Insulin Injection Revenue by Application
  9. 5.3.1 Global Long-acting Insulin Injection Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Long-acting Insulin Injection Revenue by Application (2021-2032)
  11. 5.3.3 Global Long-acting Insulin Injection Revenue Market Share by Application (2021-2032)
6 Global Long-acting Insulin Injection Sales by Region
  1. 6.1 Global Long-acting Insulin Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Insulin Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Insulin Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Long-acting Insulin Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Long-acting Insulin Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Long-acting Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Long-acting Insulin Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Long-acting Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Long-acting Insulin Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Long-acting Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Long-acting Insulin Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Long-acting Insulin Injection Revenue by Region
  1. 7.1 Global Long-acting Insulin Injection Revenue by Region
  2. 7.1.1 Global Long-acting Insulin Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Long-acting Insulin Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Long-acting Insulin Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Long-acting Insulin Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Long-acting Insulin Injection Revenue (2021-2032)
  8. 7.2.2 North America Long-acting Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Long-acting Insulin Injection Revenue (2021-2032)
  11. 7.3.2 Europe Long-acting Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Long-acting Insulin Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Long-acting Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Long-acting Insulin Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Long-acting Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 United Laboratories
  2. 8.1.1 United Laboratories Company Information
  3. 8.1.2 United Laboratories Business Overview
  4. 8.1.3 United Laboratories Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 United Laboratories Long-acting Insulin Injection Product Portfolio
  6. 8.1.5 United Laboratories Recent Developments
  7. 8.2 Tonghua Dongbao
  8. 8.2.1 Tonghua Dongbao Company Information
  9. 8.2.2 Tonghua Dongbao Business Overview
  10. 8.2.3 Tonghua Dongbao Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tonghua Dongbao Long-acting Insulin Injection Product Portfolio
  12. 8.2.5 Tonghua Dongbao Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Long-acting Insulin Injection Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novo Nordisk
  20. 8.4.1 Novo Nordisk Company Information
  21. 8.4.2 Novo Nordisk Business Overview
  22. 8.4.3 Novo Nordisk Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novo Nordisk Long-acting Insulin Injection Product Portfolio
  24. 8.4.5 Novo Nordisk Recent Developments
  25. 8.5 Eli Lilly & Co
  26. 8.5.1 Eli Lilly & Co Company Information
  27. 8.5.2 Eli Lilly & Co Business Overview
  28. 8.5.3 Eli Lilly & Co Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly & Co Long-acting Insulin Injection Product Portfolio
  30. 8.5.5 Eli Lilly & Co Recent Developments
  31. 8.6 Gan & Lee
  32. 8.6.1 Gan & Lee Company Information
  33. 8.6.2 Gan & Lee Business Overview
  34. 8.6.3 Gan & Lee Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gan & Lee Long-acting Insulin Injection Product Portfolio
  36. 8.6.5 Gan & Lee Recent Developments
  37. 8.7 Wockhardt
  38. 8.7.1 Wockhardt Company Information
  39. 8.7.2 Wockhardt Business Overview
  40. 8.7.3 Wockhardt Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Wockhardt Long-acting Insulin Injection Product Portfolio
  42. 8.7.5 Wockhardt Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Long-acting Insulin Injection Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Swixx Biopharma
  50. 8.9.1 Swixx Biopharma Company Information
  51. 8.9.2 Swixx Biopharma Business Overview
  52. 8.9.3 Swixx Biopharma Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Swixx Biopharma Long-acting Insulin Injection Product Portfolio
  54. 8.9.5 Swixx Biopharma Recent Developments
  55. 8.10 Lupin Laboratories
  56. 8.10.1 Lupin Laboratories Company Information
  57. 8.10.2 Lupin Laboratories Business Overview
  58. 8.10.3 Lupin Laboratories Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lupin Laboratories Long-acting Insulin Injection Product Portfolio
  60. 8.10.5 Lupin Laboratories Recent Developments
  61. 8.11 KALBE PHARMA
  62. 8.11.1 KALBE PHARMA Company Information
  63. 8.11.2 KALBE PHARMA Business Overview
  64. 8.11.3 KALBE PHARMA Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 KALBE PHARMA Long-acting Insulin Injection Product Portfolio
  66. 8.11.5 KALBE PHARMA Recent Developments
  67. 8.12 INFION PHARMA
  68. 8.12.1 INFION PHARMA Company Information
  69. 8.12.2 INFION PHARMA Business Overview
  70. 8.12.3 INFION PHARMA Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 INFION PHARMA Long-acting Insulin Injection Product Portfolio
  72. 8.12.5 INFION PHARMA Recent Developments
  73. 8.13 Cipla
  74. 8.13.1 Cipla Company Information
  75. 8.13.2 Cipla Business Overview
  76. 8.13.3 Cipla Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cipla Long-acting Insulin Injection Product Portfolio
  78. 8.13.5 Cipla Recent Developments
  79. 8.14 Biocon Biologics
  80. 8.14.1 Biocon Biologics Company Information
  81. 8.14.2 Biocon Biologics Business Overview
  82. 8.14.3 Biocon Biologics Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Biocon Biologics Long-acting Insulin Injection Product Portfolio
  84. 8.14.5 Biocon Biologics Recent Developments
  85. 8.15 Biocare
  86. 8.15.1 Biocare Company Information
  87. 8.15.2 Biocare Business Overview
  88. 8.15.3 Biocare Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Biocare Long-acting Insulin Injection Product Portfolio
  90. 8.15.5 Biocare Recent Developments
  91. 8.16 Abbott Laboratories
  92. 8.16.1 Abbott Laboratories Company Information
  93. 8.16.2 Abbott Laboratories Business Overview
  94. 8.16.3 Abbott Laboratories Long-acting Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Laboratories Long-acting Insulin Injection Product Portfolio
  96. 8.16.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Insulin Injection Value Chain Analysis
  2. 9.1.1 Long-acting Insulin Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Insulin Injection Production Mode & Process
  6. 9.2 Long-acting Insulin Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Insulin Injection Distributors
  9. 9.2.3 Long-acting Insulin Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst